Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00787267 | Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC(TOP0801) | Phase 2 | terminated | Nov 7, 2008 | Duke University | Poor accrual | Enrollment / accrual |
| NCT02277457 | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy… | Early Phase 1 | withdrawn | Oct 29, 2014 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT02087176 | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat… | Phase 2 | terminated | Mar 14, 2014 | AstraZeneca | The study was terminated early by the sponsor. | Other (stated, no rule matched) |
| NCT02705339 | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Phase 2 | withdrawn | Mar 10, 2016 | Washington University School of Medicine | Clovis Oncology discontinued rociletinib. | Other (stated, no rule matched) |
| NCT02651506 | Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the… | Phase 2 | withdrawn | Jan 11, 2016 | St. Joseph's Healthcare Hamilton | not stated | Not stated |
| NCT00692380 | Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable… | Phase 1 | terminated | Jun 6, 2008 | Virginia Commonwealth University | insufficient accrual | Enrollment / accrual |
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | Phase 2 | terminated | Aug 11, 2008 | Hoosier Cancer Research Network | Study terminated due to withdrawal of pharmaceutical funding | Funding |
| NCT00766246 | Phase II Avastin Trial for Stage IIIB/IV NSCLC | Phase 2 | terminated | Oct 3, 2008 | Pharmatech | Withdrawal of funding support | Funding |
| NCT01058902 | The Effect Of Aspirin On Survival in Lung Cancer | Phase 3 | withdrawn | Jan 29, 2010 | Liverpool Heart and Chest Hospital NHS Foundation Trust | failed to achive funding | Funding |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | Phase 2 | terminated | Mar 27, 2013 | National OncoVenture | Low recruitment | Enrollment / accrual |
| NCT01525446 | Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer | Early Phase 1 | terminated | Feb 3, 2012 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT01565772 | Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III… | Phase 1 | terminated | Mar 29, 2012 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT02537561 | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 1, 2015 | Washington University School of Medicine | The pharmaceutical company did not want to follow through with support for the study. | Sponsor / business decision |
| NCT02470065 | Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.(REMNANT) | Phase 2 | suspended | Jun 12, 2015 | European Organisation for Research and Treatment of Cancer - EORTC | Study never started | Other (stated, no rule matched) |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of…(DISTAL-2) | Phase 3 | terminated | Jun 27, 2006 | National Cancer Institute, Naples | slow accrual | Enrollment / accrual |
| NCT00986284 | Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non… | Phase 2 | suspended | Sep 29, 2009 | Tianjin Medical University Cancer Institute and Hospital | Lack of patients and some progressed disease soon after surgery | Other (stated, no rule matched) |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced… | Phase 3 | terminated | Dec 14, 2015 | Takeda | Sponsor decision to terminate the study because the study did not meet the primary endpoint. | Sponsor / business decision |
| NCT01193868 | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently… | Phase 2 | terminated | Sep 2, 2010 | National Cancer Institute (NCI) | Study drug production halted. | Other (stated, no rule matched) |
| NCT01577212 | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern…(IDEAL-VMAT) | Phase 2 | terminated | Apr 13, 2012 | Radboud University Medical Center | Lack of accrual | Enrollment / accrual |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | Phase 2 / Phase 3 | terminated | May 5, 2011 | Synta Pharmaceuticals Corp. | not stated | Not stated |
| NCT01411098 | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung… | Phase 1 | terminated | Aug 8, 2011 | University of Washington | Low accrual | Enrollment / accrual |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 / Phase 2 | withdrawn | Sep 1, 2015 | Erin Bertino | PI decision due to funding support | Funding |
| NCT00738881 | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating…(MARVEL) | Phase 3 | terminated | Aug 21, 2008 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell… | Phase 2 | withdrawn | Oct 7, 2008 | Eli Lilly and Company | not stated | Not stated |
| NCT00905801 | Computed Tomography (CT) Perfusion Imaging of Lung Cancer | N/A | terminated | May 21, 2009 | University of Pittsburgh | Co-PI left institution, PI not pursuing | Investigator |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment… | Phase 2 | terminated | Feb 25, 2009 | Bristol-Myers Squibb | not stated | Not stated |
| NCT02134886 | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or… | Phase 1 | terminated | May 9, 2014 | National Cancer Institute (NCI) | No Accrual | Enrollment / accrual |
| NCT01004419 | Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Oct 30, 2009 | University of Wisconsin, Madison | Support for investigational products has been withdrawn. | Other (stated, no rule matched) |
| NCT00923949 | Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Study never published; terminated early due to low accrual. | Enrollment / accrual |
| NCT01946490 | Time Trends in Waiting Times of NSCLC Patients. | — | withdrawn | Sep 19, 2013 | Maastricht Radiation Oncology | Not subsidized, will not start in the near future | Other (stated, no rule matched) |
| NCT01193881 | RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent… | Phase 1 | terminated | Sep 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00749567 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With… | Phase 2 | terminated | Sep 9, 2008 | Hellenic Oncology Research Group | Poor accrual | Enrollment / accrual |
| NCT02179567 | Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | Phase 2 | terminated | Jul 2, 2014 | Hellenic Oncology Research Group | Terminated due to poor accrual | Enrollment / accrual |
| NCT02250378 | Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early… | N/A | withdrawn | Sep 26, 2014 | University of Southern California | No accrual | Enrollment / accrual |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | Phase 3 | terminated | Apr 13, 2007 | Amgen | Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective. | Other (stated, no rule matched) |
| NCT01057212 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung… | Phase 2 | terminated | Jan 27, 2010 | Providence Health & Services | Lack of support from pharmaceutical collaborator. | Other (stated, no rule matched) |
| NCT01184287 | A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With… | Phase 2 | withdrawn | Aug 18, 2010 | Tamir Biotechnology, Inc. | Program discontinued | Other (stated, no rule matched) |
| NCT00050336 | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With… | Phase 3 | terminated | Dec 5, 2002 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00983047 | Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced… | Phase 2 | terminated | Sep 23, 2009 | Biotech Pharmaceutical Co., Ltd. | The sponsor decide to terminate | Other (stated, no rule matched) |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid… | Phase 1 | withdrawn | Jun 24, 2008 | Exelixis | Study not initiated | Other (stated, no rule matched) |
| NCT00985998 | Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced… | Phase 1 | withdrawn | Sep 29, 2009 | Biotech Pharmaceutical Co., Ltd. | no paticipants enrolled | Enrollment / accrual |
| NCT00391586 | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced… | Phase 2 | terminated | Oct 24, 2006 | New Mexico Cancer Research Alliance | PI left institution. | Investigator |
| NCT02405247 | TAURAS - T790 AURA ScreenFailure SOC Registry Study(TAURAS) | — | terminated | Apr 1, 2015 | AstraZeneca | Team's request. | Other (stated, no rule matched) |
| NCT01658332 | Circulating Tumor Cells in Lung Cancer(CIRCUBRONCH) | N/A | terminated | Aug 7, 2012 | Central Hospital, Nancy, France | unavailability of the investigator due to an overloaded planning | Investigator |
| NCT01064050 | Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers(SPOC) | Phase 4 | terminated | Feb 8, 2010 | Centre Hospitalier Universitaire de Saint Etienne | Difficulty to include patient | Other (stated, no rule matched) |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | Phase 2 | terminated | Feb 13, 2006 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00912366 | Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for… | — | terminated | Jun 3, 2009 | Medtronic - MITG | Slow Enrollment | Enrollment / accrual |
| NCT00907179 | Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | May 22, 2009 | University of Pittsburgh | Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn.. | Enrollment / accrual |
| NCT01444118 | A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in…(NSCLC) | Phase 3 | terminated | Sep 30, 2011 | Bioven Europe | The early termination is not related to safety/toxicity but to initiate new Phase III with… | Safety / toxicity |
| NCT01282151 | TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type…(TRAIL) | Phase 3 | terminated | Jan 24, 2011 | Chonnam National University Hospital | Difficulty in recruitment due to approval of maintenance pemetrexed treatment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 30, 2016source: clinicaltrials